Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain
Lekha Mikkilineni, James N. Kochenderfer(National Institutes of Health), Elisabet E. Manasanch(National Institutes of Health), Danielle Vanasse(National Institutes of Health), James Chih‐Hsin Yang(National Taiwan University Hospital), Jennifer N. Brudno(National Institutes of Health), Micaela Ganadan(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Steven A. Rosenberg(National Cancer Institute), David F. Stroncek(Yale University), Norris Lam(National Institutes of Health), Jennifer Mann(National Institutes of Health), Stephanie L. Goff(Unknown), Vicki Fellowes(National Cancer Institute), Richard M. Sherry(Unknown), Rashmika Patel(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Steven L. Highfill(National Institutes of Health), Irina Marić(Center for Cancer Research), Constance M. Yuan(National Cancer Institute)
Cited by 20
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k